The APOLO Study: A Cross-Sectional Analysis of Disease Characteristics and Patient Burden in Moderate-to-Severe Atopic Dermatitis in Portugal
Rattachement africain : pt. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
INTRODUCTION: Atopic dermatitis (AD) is a chronic inflammatory skin disease with a substantial impact on patients' quality of life (QoL). This study aimed to characterize the burden of moderate-to-severe AD in the Portuguese population, focusing on patients' QoL and socioeconomic activities while describing their treatment patterns and healthcare resource use. METHODS: This multicenter, cross-sectional, and non-interventional study in eight Portuguese referral AD centers recruited patients over 12 years old, seeking first-time AD care. Patients over 16 years old were analyzed, and data on demographics, clinical characteristics, treatment patterns, healthcare resource utilization, and burden of disease via patient-reported outcomes (PROs) were collected. RESULTS: With a predominantly White cohort, a mean age of 30.0 years, and balanced gender distribution, the study highlighted the significant impact of moderate-to-severe AD on patients' QoL, with a mean Dermatology Life Quality Index score of 15.19. High levels of itch, lesional skin severity, sleep disturbance, and pain contributed to the substantial burden of disease. Productivity was impaired in 40.0% of patients and daily activities were disrupted in 50.0%. Average body surface area involvement was 45.82%, with a mean of 6.49 AD flares in the previous year. Dermatologists played a pivotal role in the patient journey, contributing significantly to the diagnosis (55.9%) and referral process (70.9%). Treatment patterns highlighted a historical reliance on topical therapies and an evolving landscape with post-visit inclusion of advanced therapies such as dupilumab (38.5%), conventional immunosuppressants like cyclosporine (31.2%), and baricitinib (6.8%). CONCLUSION: This study unveils the intricate landscape of moderate-to-severe AD in Portugal, highlighting a substantial unmet need for optimal disease management. The role of dermatologists is crucial, yet limited adoption of advanced therapies in the face of significant disease burden prompts critical reflection.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- The APOLO Study: A Cross-Sectional Analysis of Disease Characteristics and Patient Burden in Moderate-to-Severe Atopic Dermatitis in Portugal
- Date Crossref
- 10/02/2025
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Administração Regional de Saúde de Lisboa e Vale do Tejo pays non établi dans la noticeOrganisme public
-
Hospital do Desterro pays non établi dans la noticeÉtablissement de santé
-
Hospital CUF Descobertas Dermatology Centre pays non établi dans la noticeÉtablissement de santé
-
Hospital de São João pays non établi dans la noticeÉtablissement de santé
-
University of Coimbra pays non établi dans la noticeUniversité ou école supérieure
-
Pfizer (Portugal) pays non établi dans la noticeEntreprise
-
Universidade do Porto pays non établi dans la noticeUniversité ou école supérieure
-
Dermatology Department pays non établi dans la noticeInstitution
-
University Hospital Dermatology Clinic pays non établi dans la noticeUniversité ou école supérieure
-
Faculty of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Laboratórios Pfizer pays non établi dans la noticeInstitution
-
Department of Dermatology pays non établi dans la noticeInstitution
Administração Regional de Saúde de Lisboa e Vale do Tejo, Hospital do Desterro et Dermatology Centre — Hospital CUF Descobertas, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.